WO2000014263A8 - Recombinant hepatitis a virus (hav), hav variants, hav-based vaccines and methods of producing them - Google Patents

Recombinant hepatitis a virus (hav), hav variants, hav-based vaccines and methods of producing them

Info

Publication number
WO2000014263A8
WO2000014263A8 PCT/US1999/020375 US9920375W WO0014263A8 WO 2000014263 A8 WO2000014263 A8 WO 2000014263A8 US 9920375 W US9920375 W US 9920375W WO 0014263 A8 WO0014263 A8 WO 0014263A8
Authority
WO
WIPO (PCT)
Prior art keywords
hav
variants
virus
methods
recombinant hepatitis
Prior art date
Application number
PCT/US1999/020375
Other languages
French (fr)
Other versions
WO2000014263A9 (en
WO2000014263A3 (en
WO2000014263A2 (en
Inventor
Stanley M Lemon
Michael R Beard
Original Assignee
Univ Texas
Stanley M Lemon
Michael R Beard
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas, Stanley M Lemon, Michael R Beard filed Critical Univ Texas
Publication of WO2000014263A2 publication Critical patent/WO2000014263A2/en
Publication of WO2000014263A3 publication Critical patent/WO2000014263A3/en
Publication of WO2000014263A8 publication Critical patent/WO2000014263A8/en
Publication of WO2000014263A9 publication Critical patent/WO2000014263A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention described herein is directed to methods and compositions involving recombinant hepatitis A virus (HAV) expressing heterologous nucleic acid sequences and a forced selection method to identify viral variants, including HAV variants, that may contain characteristics beneficial for a vaccine. Accordingly, the invention includes HAV-based vaccine virus seed and other viral vaccine seed, including methods of making them. The viruses of the present invention also generally have diagnostic uses as well as therapeutic uses for gene therapy, especially with respect to liver-specific diseases and conditions.
PCT/US1999/020375 1998-09-03 1999-09-03 Recombinant hepatitis a virus (hav), hav variants, hav-based vaccines and methods of producing them WO2000014263A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9894598P 1998-09-03 1998-09-03
US60/098,945 1998-09-03

Publications (4)

Publication Number Publication Date
WO2000014263A2 WO2000014263A2 (en) 2000-03-16
WO2000014263A3 WO2000014263A3 (en) 2000-08-17
WO2000014263A8 true WO2000014263A8 (en) 2001-03-15
WO2000014263A9 WO2000014263A9 (en) 2001-11-22

Family

ID=22271678

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/020375 WO2000014263A2 (en) 1998-09-03 1999-09-03 Recombinant hepatitis a virus (hav), hav variants, hav-based vaccines and methods of producing them

Country Status (1)

Country Link
WO (1) WO2000014263A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6921634B2 (en) 1999-12-23 2005-07-26 Board Of Regents, The University Of Texas System Replication competent hepatitus C virus and methods of use
DK1694694T3 (en) 2003-12-01 2013-05-06 Univ Texas Replication competent hepatitis C virus as well as methods of use
GEP20156313B (en) 2010-09-22 2015-07-10 Alios Biopharma Inc Substituted nucleotide analogs
EP2794630A4 (en) 2011-12-22 2015-04-01 Alios Biopharma Inc Substituted phosphorothioate nucleotide analogs
CN104321333A (en) 2012-03-21 2015-01-28 沃泰克斯药物股份有限公司 Solid forms of a thiophosphoramidate nucleotide prodrug
WO2013142157A1 (en) 2012-03-22 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
CN104862287A (en) * 2015-05-21 2015-08-26 中国医学科学院医学生物学研究所 Preparation method of genetic engineering recombinant combined vaccine against hepatitis A and hepatitis E

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478746A (en) * 1982-04-07 1995-12-26 The United States Of America As Represented By The Department Of Health And Human Services cDNA encoding attenuated cell culture adapted hepatitis A virus genome
FR2619012B1 (en) * 1987-08-07 1989-12-22 Pasteur Institut VACCINES IN WHICH THE CHARACTERISTIC EPITOPE IS INCORPORATED IN A PROTEIN OF PICORNAVIRUS, ESPECIALLY POLIOVIRUS
EP0702724A1 (en) * 1993-06-03 1996-03-27 Institut Pasteur Mengovirus as a vector for expression of foreign polypeptides
WO1997040166A2 (en) * 1996-04-19 1997-10-30 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Simian-human hav having a chimeric 2c protein

Also Published As

Publication number Publication date
WO2000014263A9 (en) 2001-11-22
WO2000014263A3 (en) 2000-08-17
WO2000014263A2 (en) 2000-03-16

Similar Documents

Publication Publication Date Title
CN112226445B (en) Nucleic acid for coding spike protein of SARS-CoV-2 virus and its application
RU2003118436A (en) ANKARA MODIFIED VERSION OF ANKARA
RU98101904A (en) RECOMBINANT MVA VIRUS AND ITS USE
WO2001039797A3 (en) Artificial chromosome constructs containing nucleic acid sequences capable of directing the formation of a recombinant rna-virus
EP1016418A3 (en) Composition comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immunostimulatory molecule
CA2170412A1 (en) Modified plant viruses as vectors of heterologous peptides
CN101142319B (en) Vaccines based on the use of mv
WO2000014263A8 (en) Recombinant hepatitis a virus (hav), hav variants, hav-based vaccines and methods of producing them
WO2002014362A3 (en) A hepatitis c virus non-structural ns3/4a fusion gene
US9968672B2 (en) IDNA vaccines and methods for using the same
EP1149917A3 (en) Hepatitis B virus vectors for gene therapy
WO2002022687A3 (en) Viral chemokine-tumur antigen fusion proteins
WO2000073476A1 (en) Vector for integration of heterologous sequences into poxviral genomes
WO2000034445A3 (en) Live attenuated venezuelan equine encephalitis vaccine
FR2600079B1 (en) VIRAL VECTOR AND RECOMBINANT DNA ENCODING PROTEIN F OF THE VIRUS CAUSAL AGENT OF THE S.I.D.A, CELL CULTURE INFECTED WITH THIS VECTOR, PROCESS FOR PREPARING THE PROTEIN, OBTAINED PROTEIN, VACCINE AND ANTIBODIES OBTAINED
JP2011135897A (en) Modified nodavirus rna for gene delivery
WO2002028174A1 (en) Methods of infection with hepatitis c virus
DE19712899C1 (en) Process for the production of non-infectious recombinant picornavirus particles
HUP0200320A2 (en) Recombinant virus expressing foreign dna encoding feline cd80, feline ctla-4 or feline cd86 and uses thereof
WO2003025002A3 (en) Method and compositions of defensin-antigen fusion proteins and chemokine-antigen fusion proteins as vaccines for tumors and viral infection
EP0789563B8 (en) Hepatitis virus b and c vaccines
CN1322120C (en) Bivalent hepatitis B-encephalitis B vaccine
TH58373B (en) Enhanced immunogens For vaccines that are not stimulated to fight infectious diseases caused by the Genes family. Ensifalitis virus And a method to produce that
RU2175555C2 (en) Method of interferon virus-inductor preparing
TH63069A (en) Infectious mud

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 09564065

Country of ref document: US

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: C1

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i
AK Designated states

Kind code of ref document: C2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

COP Corrected version of pamphlet

Free format text: PAGES 1/2-2/2, DRAWINGS, REPLACED BY NEW PAGES 1/2-2/2; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

122 Ep: pct application non-entry in european phase